vaccine Pfizer is co-developing with Germany’s BioNTech SE to two doses of a placebo. While the doctors and subjects in the trial don’t know who got the vaccine -- a measure to avoid bias -- a committee of outside experts that knows which people received the shot is reviewing safety data on a weekly basis, Pfizer executives said during the investor meeting.“They would notify us if they had any safety concerns and have not done that to date," Kathrin Jansen, Pfizer’s head of vaccine research, said during the meeting.
The company’s own scientists are also looking for worrisome adverse events that haven’t appeared so far. Fatigue has been the most common side effect seen in the trial thus far, according to the Pfizer presentation.Pfizer.